Exhibit 99.1

To the shareholders of

NLS Pharmaceutics AG, Zurich, Switzerland

Zurich, 9 May 2022

Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics AG, Zurich, Switzerland

Dear Shareholder,

The board of directors of NLS Pharmaceutics AG (the “Board of Directors”), with registered office at the Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invite you to the ordinary shareholders’ meeting of the Company. The shareholders’ meeting will be held as follows:

Due to the current restrictions resulting from the global COVID-19 pandemic, the meeting will be held in accordance with art. 27 para. 1 letter b COVID-19-Ordinance 3, i.e., without physical presence of the shareholders. Shareholders will have the possibility to exercise their shareholder rights only through the independent proxy, KBT Treuhand AG Zürich, Kreuzplatz 5, 8032 Zurich, Switzerland, (represented by Sandro Müller) which was elected as independent proxy at the ordinary shareholders’ meeting held on June 17, 2021, until the next annual ordinary shareholders’ meeting. Although you will not attend the meeting, your vote is important.

Please find enclosed to your individual invitation a Proxy Card. The agenda items to be voted on and the voting instructions for the proxy are provided below:

The agenda items and proposals of the Board of Directors are as follows:

Proposal

The Board of Directors proposes to elect KBT Treuhand AG Zürich, Kreuzplatz 5, 8032 Zurich, Switzerland (represented by Sandro Müller), as independent proxy until the next annual ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes the approval of the statutory financial statements of the Company for the business year 2021.

Proposal

The Board of Directors proposes the approval of the compensation report for the business year 2021.

Proposal

The Board of Directors proposes that the shareholders approve that the net loss of CHF 7,442,309 for the business year 2021 is added to the loss brought forward of CHF 7,027,832 resulting in a new balance of loss brought forward of CHF 14,470,141.

Proposal

The Board of Directors proposes that the shareholders grant discharge to each member of the Board of Directors and of the Executive Management from liabilities for their activities for the business year 2021.

Proposal

The Board of Directors proposes to re-elect Ronald Hafner as Chairman of the Board of Directors and Alexander Zwyer, Myoung-Ok Kwon, Stig Lökke Pedersen and Gian-Marco Rinaldi Diaz de la Cruz as members of the Board of Directors for another term lasting until the next annual ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes that Ronald Hafner and Myoung-Ok Kwon shall be elected as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes to re-elect PricewaterhouseCoopers AG, Zurich, as auditor of the Company for another term lasting until the next annual ordinary shareholders’ meeting.

According to Swiss law, by amending the articles of association, the general meeting may authorise the Board of Directors to increase the share capital within a period of no more than two years. Such authorised capital may not exceed one-half of the existing share capital. The Company will conduct a capital increase prior to the ordinary shareholders’ meeting, thus resulting in a new existing share capital of CHF 391’290.24. The calculation of the authorized share capital of the Company for this invitation is therefore based on this new existing share capital of CHF 391’290.24.

Proposal

The Board of Directors proposes that the authorized share capital of the Company shall be renewed until May 31, 2024 and shall equal to the maximum amount of CHF 195’645.12 (article 3a of the articles of association). Therefore, paragraph 1 of article 3a of the articles of association shall be amended as follows:

It being understood that article 3a paragraph 2 and 3 of the articles of association shall remain unchanged.

According to Swiss law, the general meeting may resolve to make a conditional capital increase. The nominal amount by which the share capital may be increased in this conditional manner must not exceed one-half of the existing share capital. The Company will conduct a capital increase prior to the ordinary shareholders’ meeting, thus resulting in a new existing share capital of CHF 391’290.24. The calculation of the conditional share capital of the Company for this invitation is therefore based on this new existing share capital of CHF 391’290.24.

It being understood that article 3c paragraph 2 of the articles of association shall remain unchanged.

Proposal

The Board of Directors proposes the approval of the maximum aggregate amount of CHF 130’000 (cash base compensation plus social security costs) for the fixed compensation of the members of the Board of Directors for the previous term of office from the previous ordinary shareholders’ meeting held on June 17, 2021 until this ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes the approval of the maximum aggregate amount of CHF 143’000 (cash base compensation plus social security costs) for the fixed compensation of the members of the Board of Directors for the following term of office lasting until the next ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes the approval of the grant of equity or equity linked instruments with maximum aggregate amount of CHF 444’106 (equity or equity linked instruments plus social security costs) for the compensation of the members of the Board of Directors for the following term of office lasting until the next ordinary shareholders’ meeting.

Proposal

The Board of Directors proposes the approval of the maximum aggregate amount of CHF 1’762’500 (cash compensation plus social security costs) for the fixed compensation of the members of the Executive Management for the financial year 2023.

Proposal

The Board of Directors proposes the approval of the maximum aggregate amount of CHF 601’700 (cash compensation plus social security costs) for the variable compensation of the members of the Executive Management for the financial year 2023.

Proposal

The Board of Directors proposes the approval of the grant of equity or equity linked instruments with maximum aggregate amount of CHF 991’838 (equity or equity linked instruments plus social security costs) for the members of the Executive Management for the financial year 2023.

Administrative Information

Please note the following instructions with respect to the participation in the ordinary shareholders’ meeting:

Shareholders who are entered in the shareholder register maintained by our transfer Agent VStock Transfer, LLC as of April 30, 2022, 10 pm CET (reporting date) are entitled to exercise their shareholder rights with respect to the ordinary shareholders’ meeting. During the period from April 30, 2022 until and including May 31 2022, no entries of shares will be made in the shareholder register.

In light of the current epidemic situation in Switzerland and the corresponding legal basis, there will be no physical attendance of shareholders at the ordinary shareholders’ meeting. Based on art. 27 para. 1 letter b COVID-19-Ordinance 3 the shareholders will have the possibility to exercise their shareholders’ rights through the independent proxy only.

Shareholders may only be represented by the independent proxy, KBT Treuhand AG Zürich, Kreuzplatz 5, 8032 Zurich, Switzerland (represented by Sandro Müller). The independent proxy will be physically present at the ordinary shareholders’ meeting to vote on behalf of the shareholders who issued instructions to him.

If the independent proxy cannot be present, the Board of Directors will appoint a new independent proxy. The powers of attorney granted to the independent proxy will also be valid for any new independent proxy appointed by the Board of Directors.

In order to authorize the independent proxy, the shareholders may vote by returning the marked, signed and dated Proxy Card by e-mail or mail in line with the instructions given therein, or by voting on the internet (go to http://www.vstocktransfer.com/proxy, click on Proxy Voter Login and log-on using the control number provided in the Proxy Card). Voting instructions must be given no later than May 30, 2022 (received by 12:00 CET).

As of May 10, 2022, the statutory financial statements and the compensation report including the report of statutory auditors, for the financial year 2021 can be accessed on our website at: https://nlspharma.com/investors/financial-information/.

All documents have likewise been laid out for inspection at the headquarters of the Company.

Yours sincerely,

On behalf of the Board of Directors of NLS Pharmaceutics AG

Enclosures:

- Proxy Card

Please Vote, Sign, Date and Return Promptly in the Enclosed Envelope. ALL VOTES MUST BE RECEIVED BY MAY 30, 2022.

Annual General Meeting Proxy Card - NLS Pharmaceutics Ltd.

The Board of Directors recommends a vote of “FOR” for Proposals 1-11.6.

DETACH PROXY CARD HERE TO VOTE BY MAIL

To change the address on your account, please check the box at right and indicate your new address.      

NLS PHARMACEUTICS LTD.

Annual Meeting of Shareholders

May 31, 2022

The undersigned, a shareholder of NLS Pharmaceutics Ltd., (the “Company”), hereby appoints KBT Treuhand AG Zurich represented by Sandro Mueller and proxy of the undersigned, with full power of substitution, for and in the name of the undersigned, to vote and otherwise act on behalf of the undersigned at the annual general meeting of shareholders of the Company to be held on Tuesday, May 31, 2022, at the premises of Wenger Vieli AG, Metallstrasse 9, 6302 Zug, Switzerland, at 4:00 p.m. CET (10:00 a.m. EST), or at any adjournment(s) or postponement(s) thereof, with respect to all of the ordinary shares, of the Company (the “Shares”) which the undersigned would be entitled to vote, with all powers the undersigned would possess if personally present, provided said proxies are authorized and directed to vote as indicated with respect to the matter set forth below this Proxy. The undersigned herewith acknowledges all actions and declarations of his/her/its proxy or the substitutes as legally binding for him/her/it. All shares represented by properly executed proxies received prior to or at the Meeting and not revoked prior to, or at, the Meeting in accordance with the procedures described in the proxy statement, will be voted as specified in the instructions indicated in such proxies. Subject to applicable law, in the absence of instructions, the shares represented by properly executed and received proxies will be voted “FOR” all of the proposed resolutions to be presented at the Meeting for which the Board recommends a vote “FOR” Proposals 1 through 11.6.

For all disputes arising out of or in connection with this Proxy, the ordinary courts at the registered domicile of the Company are exclusively competent. All obligations and rights arising out of or in connection with this proxy are governed by Swiss Law. The undersigned herewith expressively declares to indemnify the proxy or the substitutes for any direct or indirect damages arising out of or in connection with the actions referred to in this proxy card.

This proxy also delegates, to the extent permitted by applicable law, discretionary authority to vote with respect to all other business and legal acts which the undersigned could carry out in the event of his/her/its personal presence at the annual meeting of shareholders as well as to make any changes required due to objections by the commercial register and to any adjournment(s) or postponement(s) thereof.

PLEASE COMPLETE, DATE AND SIGN THIS FORM OF PROXY AND E-MAIL OR MAIL THE ENTIRE PROXY PROMPTLY, IN ACCORDANCE WITH THE INFORMATION PROVIDED ON THE FRONT PAGE, IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES. IF THE FORM OF PROXY IS MAILED IN THE UNITED STATES IN THE ENCLOSED ENVELOPE, NO POSTAGE NEED BE AFFIXED.

DETACH PROXY CARD HERE TO VOTE BY MAIL